S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:VRTX

Vertex Pharmaceuticals Competitors

$211.98
+4.19 (+2.02 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$206.39
Now: $211.98
$212.60
50-Day Range
$207.02
MA: $219.81
$241.31
52-Week Range
$197.47
Now: $211.98
$306.08
Volume1.70 million shs
Average Volume2.20 million shs
Market Capitalization$55.11 billion
P/E Ratio26.77
Dividend YieldN/A
Beta0.79

Competitors

Vertex Pharmaceuticals (NASDAQ:VRTX) Vs. AMGN, GILD, REGN, BIIB, ALXN, and SGEN

Should you be buying VRTX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Vertex Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), and Seagen (SGEN).

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Amgen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vertex Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042212.89
Amgen0111402.56

Vertex Pharmaceuticals currently has a consensus target price of $292.68, indicating a potential upside of 38.07%. Amgen has a consensus target price of $257.2174, indicating a potential upside of 12.95%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Profitability

This table compares Vertex Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Amgen29.42%95.55%15.52%

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Amgen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.41
Amgen$23.36 billion5.63$7.84 billion$14.8215.37

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Amgen on 11 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Volatility & Risk

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a summary of recent recommendations and price targets for Gilead Sciences and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences1111202.46
Vertex Pharmaceuticals042212.89

Gilead Sciences currently has a consensus price target of $96.0370, indicating a potential upside of 48.62%. Vertex Pharmaceuticals has a consensus price target of $292.68, indicating a potential upside of 38.07%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Vertex Pharmaceuticals.

Earnings & Valuation

This table compares Gilead Sciences and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.62$5.39 billion$6.1410.52
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.41

Gilead Sciences has higher revenue and earnings than Vertex Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Gilead Sciences on 9 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings for Regeneron Pharmaceuticals and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061512.77
Vertex Pharmaceuticals042212.89

Regeneron Pharmaceuticals currently has a consensus target price of $625.8077, suggesting a potential upside of 35.58%. Vertex Pharmaceuticals has a consensus target price of $292.68, suggesting a potential upside of 38.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Vertex Pharmaceuticals38.51%28.55%20.68%

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.29$2.12 billion$21.4721.50
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.41

Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations for Vertex Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042212.89
Biogen5151202.22

Vertex Pharmaceuticals currently has a consensus target price of $292.68, suggesting a potential upside of 38.07%. Biogen has a consensus target price of $304.4667, suggesting a potential upside of 12.47%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Biogen.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Biogen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.41
Biogen$14.38 billion2.87$5.89 billion$33.578.06

Biogen has higher revenue and earnings than Vertex Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Biogen35.63%51.00%23.54%

Summary

Vertex Pharmaceuticals beats Biogen on 10 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations for Alexion Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals016712.38
Vertex Pharmaceuticals042212.89

Alexion Pharmaceuticals currently has a consensus price target of $155.00, suggesting a potential upside of 3.26%. Vertex Pharmaceuticals has a consensus price target of $292.68, suggesting a potential upside of 38.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Vertex Pharmaceuticals38.51%28.55%20.68%

Risk & Volatility

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion6.61$2.40 billion$9.7415.41
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.41

Alexion Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen25.34%20.46%16.67%
Vertex Pharmaceuticals38.51%28.55%20.68%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Seagen and Vertex Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen151112.67
Vertex Pharmaceuticals042212.89

Seagen currently has a consensus price target of $188.4615, indicating a potential upside of 26.19%. Vertex Pharmaceuticals has a consensus price target of $292.68, indicating a potential upside of 38.07%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Seagen.

Risk & Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seagen and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million29.52$-158,650,000.00($1.33)-112.29
Vertex Pharmaceuticals$4.16 billion13.24$1.18 billion$4.2949.41

Vertex Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Seagen on 10 of the 14 factors compared between the two stocks.

Ad Legacy Research
Man Gets Into a Tesla… What Happens Next Will Shock Everyone (Video)
"Hi, I'm Jeff Brown… I'm about to get in this Tesla and drive up to a location just a few miles from here to show you Elon Musk's next big project… What happens next will shock you…"

Vertex Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$227.73+2.6%$131.53 billion$23.36 billion18.37Dividend Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Gilead Sciences logo
GILD
Gilead Sciences
2.8$64.62+2.2%$81.20 billion$22.45 billion66.62Analyst Downgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$461.57+2.6%$49.45 billion$7.86 billion16.87Gap Up
Biogen logo
BIIB
Biogen
1.9$270.71+2.6%$41.24 billion$14.38 billion8.96News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$150.10+1.1%$33.00 billion$4.99 billion35.07Unusual Options Activity
News Coverage
Seagen logo
SGEN
Seagen
1.7$149.35+2.6%$27.06 billion$916.71 million58.80Insider Selling
Decrease in Short Interest
Gap Up
Exact Sciences logo
EXAS
Exact Sciences
1.8$121.64+0.5%$20.57 billion$876.29 million-55.04Analyst Upgrade
Insider Selling
Incyte logo
INCY
Incyte
1.9$80.26+3.4%$17.64 billion$2.16 billion-51.12Gap Up
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$143.39+4.2%$16.78 billion$219.75 million-18.31Gap Up
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.73+1.8%$14.13 billion$1.70 billion17.79Analyst Revision
Novavax logo
NVAX
Novavax
1.4$174.84+9.6%$11.13 billion$18.66 million-33.49Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
Repligen logo
RGEN
Repligen
1.5$186.19+1.6%$10.20 billion$270.24 million227.06Analyst Report
Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.23+0.3%$8.76 billion$788.10 million100.25Analyst Report
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$52.78+2.9%$7.43 billion$1.12 billion109.96Analyst Report
Gap Up
United Therapeutics logo
UTHR
United Therapeutics
1.9$164.34+2.4%$7.32 billion$1.45 billion15.55Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$22.33+4.6%$6.97 billion$967.78 million46.52Insider Selling
Gap Up
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.91+1.2%$5.53 billion$195.99 million255.69
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$92.31+1.6%$4.92 billion$1.11 billion29.68Analyst Upgrade
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$73.57+2.8%$4.44 billion$806.43 million-10.42Analyst Report
Analyst Revision
Gap Up
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.24+0.1%$3.98 billion$36.13 million-85.43Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
Gap Down
Alkermes logo
ALKS
Alkermes
1.2$19.28+5.5%$3.07 billion$1.17 billion-41.91Analyst Revision
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.22+0.7%$2.83 billion$901.90 million-23.44
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.48+1.2%$2.77 billion$182.24 million-9.11Earnings Announcement
Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.40+1.9%$2.40 billion$120.28 million-145.86Decrease in Short Interest
News Coverage
Gap Up
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.84+2.1%$2.09 billion$638.60 million-10.71Analyst Report
Decrease in Short Interest
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.15+2.1%$1.98 billion$48.83 million-14.67
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$116.28+3.6%$1.86 billionN/A-10.50Analyst Report
Analyst Revision
News Coverage
Gap Up
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.95+6.6%$1.79 billion$82.27 million-21.83Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36+1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.11+1.2%$1.63 billion$428.41 million14.65Insider Buying
Innoviva logo
INVA
Innoviva
1.4$11.51+3.9%$1.17 billion$261.02 million5.87Gap Up
Codexis logo
CDXS
Codexis
1.5$19.51+2.6%$1.16 billion$68.46 million-55.74Analyst Upgrade
Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$26.21+3.9%$1.04 billion$3.57 million-11.75News Coverage
Gap Up
BOLT
Bolt Biotherapeutics
1.6$30.03+4.2%$1.04 billionN/A0.00Analyst Report
Analyst Revision
Gap Up
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.25+4.2%$1.00 billion$227.19 million50.68Insider Selling
Gap Up
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.23+3.0%$931.53 million$35.22 million-6.00Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$4.29+0.5%$919.31 million$150,000.00-6.13Analyst Downgrade
MannKind logo
MNKD
MannKind
1.4$3.67+7.9%$907.07 million$63.04 million-17.48Analyst Upgrade
Analyst Revision
Gap Up
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$6.78+1.8%$821.63 million$322.07 million-6.46Upcoming Earnings
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$20.66+6.4%$682.11 million$252 million-2.11Analyst Report
Analyst Revision
Gap Up
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.84+6.8%$648.89 million$59.29 million-25.60Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Agenus logo
AGEN
Agenus
1.6$3.20+1.3%$608.48 million$150.05 million-2.94
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.58+1.4%$583.28 million$143.01 million-1.06
Geron logo
GERN
Geron
1.4$1.80+1.7%$558.85 million$460,000.00-5.14Upcoming Earnings
Gap Up
Curis logo
CRIS
Curis
1.3$9.47+3.6%$557.00 million$10 million-11.55Increase in Short Interest
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$11.09+6.0%$554.10 million$22.27 million-5.44Upcoming Earnings
Gap Up
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.29+2.7%$480.08 million$109.33 million-2.42Upcoming Earnings
Gap Up
XOMA logo
XOMA
XOMA
1.6$36.95+4.3%$407.26 million$18.37 million-33.29Upcoming Earnings
Decrease in Short Interest
Gap Up
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$4.11+0.5%$385.12 million$36.63 million-4.84Analyst Upgrade
High Trading Volume
Gap Down
Verastem logo
VSTM
Verastem
1.5$2.22+0.0%$376.90 million$17.46 million-1.57Upcoming Earnings
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.